Ningbo Menovo Pharmaceutical Co., Ltd.SSE: 603538

in 2026

Jan 8, 2026 · Issued by Ningbo Menovo Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 8, 2026

On 6ix: 6ix.com/news/in-2026-5

Announcement on Interest Payment for “Menovo Convertible Bond” in 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Ningbo Menovo Pharmaceutical Co., Ltd. on 6ix

Earlier from Ningbo Menovo Pharmaceutical

Announcement on Self-exercise Results of Initially Granted Portion in the 3rd Exercise Period of the 2021 Stock Option Incentive and Restricted Stock Plan and Share ChangesDec 31, 2025
Announcement on Resolutions of the 22nd Meeting of the 5th Board of DirectorsDec 25, 2025
Announcement on CDE’s Technical Review of the Drug Substance Atorvastatin Calcium by the Holding SubsidiaryDec 19, 2025
Announcement on Resolutions of the 21st Meeting of the 5th Board of DirectorsDec 16, 2025
Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Febuxostat TabletsDec 11, 2025

Later from Ningbo Menovo Pharmaceutical

Indicative Announcement on the Expected Meeting of Conditions for Downward Correction of Conversion Price for "Menovo Convertible Bonds"Jan 10
Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Adempas Riociguat TabletsJan 13
Notice on Convening the 1st Extraordinary General Meeting in 2026Jan 17
Announcement on the Subsidiary Re-certified as High-tech EnterpriseJan 23
Announcement on Expected Increase in Performance for 2025Jan 27

All Ningbo Menovo Pharmaceutical news releases

Follow Ningbo Menovo Pharmaceutical into a list and get an email when it puts out news.

Follow Ningbo Menovo Pharmaceutical